BioNtech (BNTX) is one of the companies at the front-line of the battle against the coronavirus. On Friday, the company announced positive progress in the development of its COVID-19 vaccine candidate (in partnership with Pfizer).In the Phase 1 study of BNT162b2, the candidate exhibited a strong ability to induce an immune response in both young and older adults. Less than 20% of the study’s subjects had symptoms of mild to moderate fever,and only a small percentage suffered more serious events. Overall, the candidate was generally well tolerated.J.P. Morgan analyst Cory Kasimov is not surprised BNT162b2 demonstrated a better safety profile …read more
Source:: Yahoo Finance
